• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

人血管活性肠肽受体:通过结肠上皮细胞中的共价交联进行分子鉴定。

The human vasoactive intestinal peptide receptor: molecular identification by covalent cross-linking in colonic epithelium.

作者信息

Couvineau A, Laburthe M

出版信息

J Clin Endocrinol Metab. 1985 Jul;61(1):50-5. doi: 10.1210/jcem-61-1-50.

DOI:10.1210/jcem-61-1-50
PMID:2987295
Abstract

To characterize the molecular components of the vasoactive intestinal peptide (VIP) receptor in human intestine, [125I]VIP was covalently bound to human colonic epithelial membranes using dithio-bis(succinimidyl propionate). Sodium dodecyl sulfate-polyacrylamide gel autoradiographic studies of affinity labeled membranes revealed three major bands corresponding to [125I]VIP-protein complexes of 66,000, 33,000, and 16,000 mol wt. Labeling of the 66,000 and 33,000 mol wt complexes was specific, since it was abolished by VIP, while labeling of the 16,000 mol wt complex was not. Densitometric scanning of autoradiographs indicated that labeling of the 66,000 mol wt complex was inhibited by low VIP concentrations in the 10(-10)-10(-8) M range, but was unaffected by glucagon or octa-cholecystokinin. It was also reduced by VIP-(2-28), with a potency 1/100th that of VIP, and by GTP in the concentration range of 10(-7)-10(-3) M. The 33,000 mol wt complex behaved similarly to the 66,000 mol wt complex with respect to specificity and GTP sensitivity, but differed in one major feature, its affinity for VIP. Its labeling was inhibited by native VIP concentrations in the 10(-9)-10(-7) M range. Assuming one molecule of [125I]VIP bound per molecule of protein, two proteins of 63,000 and 30,000 mol wt were identified as VIP-binding sites. The 63,000 mol wt protein had the properties expected for the VIP receptor coupled to adenylate cyclase in human colon, while the 30,000 mol wt protein was a low affinity binding site. Treatment of human colonic membranes with the sulfhydryl reducing agent dithiothreitol before [125I]VIP binding strongly reduced the labeling of the two proteins. This finding does not support the hypothesis that the low affinity 30,000 mol wt binding site may be a monomer of the high affinity binding site.

摘要

为了鉴定人肠道中血管活性肠肽(VIP)受体的分子成分,使用二硫代双(琥珀酰亚胺丙酸酯)将[125I]VIP共价结合到人结肠上皮细胞膜上。对亲和标记膜进行十二烷基硫酸钠-聚丙烯酰胺凝胶放射自显影研究,结果显示有三条主要条带,分别对应分子量为66,000、33,000和16,000的[125I]VIP-蛋白质复合物。分子量为66,000和33,000复合物的标记具有特异性,因为VIP可将其消除,而分子量为16,000复合物的标记则不受影响。对放射自显影片进行光密度扫描表明,分子量为66,000复合物的标记在10(-10)-10(-8)M范围内会受到低浓度VIP的抑制,但不受胰高血糖素或八肽胆囊收缩素的影响。它也会被VIP-(2-28)(其效力为VIP的1/100)以及浓度在10(-7)-10(-3)M范围内的GTP所降低。分子量为33,000的复合物在特异性和对GTP的敏感性方面与分子量为66,000的复合物表现相似,但在一个主要特征上有所不同,即它对VIP的亲和力。其标记在10(-9)-10(-7)M范围内的天然VIP浓度下会受到抑制。假设每个蛋白质分子结合一分子[125I]VIP,则鉴定出两种分子量分别为63,000和30,000的蛋白质为VIP结合位点。分子量为63,000的蛋白质具有人结肠中与腺苷酸环化酶偶联的VIP受体所预期的特性,而分子量为30,000的蛋白质是一个低亲和力结合位点。在进行[125I]VIP结合之前,用巯基还原剂二硫苏糖醇处理人结肠膜,会强烈降低这两种蛋白质的标记。这一发现不支持低亲和力的分子量为30,000的结合位点可能是高亲和力结合位点单体的假说。

相似文献

1
The human vasoactive intestinal peptide receptor: molecular identification by covalent cross-linking in colonic epithelium.人血管活性肠肽受体:通过结肠上皮细胞中的共价交联进行分子鉴定。
J Clin Endocrinol Metab. 1985 Jul;61(1):50-5. doi: 10.1210/jcem-61-1-50.
2
Molecular identification of receptors for vasoactive intestinal peptide in rat intestinal epithelium by covalent cross-linking. Evidence for two classes of binding sites with different structural and functional properties.通过共价交联对大鼠肠上皮中血管活性肠肽受体进行分子鉴定。存在两类具有不同结构和功能特性的结合位点的证据。
Eur J Biochem. 1984 Feb 15;139(1):181-7. doi: 10.1111/j.1432-1033.1984.tb07992.x.
3
The rat liver vasoactive intestinal peptide binding site. Molecular characterization by covalent cross-linking and evidence for differences from the intestinal receptor.大鼠肝脏血管活性肠肽结合位点。通过共价交联进行分子特征分析及与肠道受体存在差异的证据。
Biochem J. 1985 Jan 15;225(2):473-9. doi: 10.1042/bj2250473.
4
Molecular identification and structural requirement of vasoactive intestinal peptide (VIP) receptors in the human colon adenocarcinoma cell line, HT-29.人结肠腺癌细胞系HT-29中血管活性肠肽(VIP)受体的分子鉴定及结构要求
Biochem J. 1985 Oct 1;231(1):139-43. doi: 10.1042/bj2310139.
5
Molecular characteristics and peptide specificity of vasoactive intestinal peptide receptors from rat cerebral cortex.大鼠大脑皮层血管活性肠肽受体的分子特征及肽特异性
J Neurochem. 1986 Nov;47(5):1469-75. doi: 10.1111/j.1471-4159.1986.tb00780.x.
6
Characterization and solubilization of vasoactive intestinal peptide receptors from rat lung membranes.大鼠肺膜血管活性肠肽受体的特性鉴定与增溶
Endocrinology. 1987 Jun;120(6):2442-52. doi: 10.1210/endo-120-6-2442.
7
Pharmacology, molecular identification and functional characteristics of vasoactive intestinal peptide receptors in human breast cancer cells.人乳腺癌细胞中血管活性肠肽受体的药理学、分子鉴定及功能特性
Cancer Res. 1988 Sep 15;48(18):5079-83.
8
Characterization of receptors for VIP on pancreatic acinar cell plasma membranes using covalent cross-linking.利用共价交联法对胰腺腺泡细胞质膜上血管活性肠肽受体的特性进行研究。
Am J Physiol. 1987 Mar;252(3 Pt 1):G404-12. doi: 10.1152/ajpgi.1987.252.3.G404.
9
Covalent cross-linking of vasoactive intestinal polypeptide to its receptors on intact human lymphoblasts.血管活性肠肽与完整人淋巴母细胞上其受体的共价交联。
J Biol Chem. 1985 Jan 25;260(2):1243-7.
10
Characterization of a common VIP-PACAP receptor in human small intestinal epithelium.人小肠上皮中一种常见的血管活性肠肽-垂体腺苷酸环化酶激活肽受体的特性研究
Am J Physiol. 1993 Feb;264(2 Pt 1):E294-300. doi: 10.1152/ajpendo.1993.264.2.E294.

引用本文的文献

1
Identifying Receptors for Neuropeptides and Peptide Hormones: Challenges and Recent Progress.鉴定神经肽和肽类激素的受体:挑战与最新进展。
ACS Chem Biol. 2021 Feb 19;16(2):251-263. doi: 10.1021/acschembio.0c00950. Epub 2021 Feb 4.
2
PET imaging of VPAC1 expression in experimental and spontaneous prostate cancer.实验性和自发性前列腺癌中VPAC1表达的正电子发射断层扫描(PET)成像
J Nucl Med. 2008 Jan;49(1):112-21. doi: 10.2967/jnumed.107.043703. Epub 2007 Dec 12.
3
Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating peptide (PACAP) receptor specific peptide analogues for PET imaging of breast cancer: In vitro/in vivo evaluation.
用于乳腺癌PET成像的血管活性肠肽(VIP)和垂体腺苷酸环化酶激活肽(PACAP)受体特异性肽类似物:体外/体内评估
Regul Pept. 2007 Dec 4;144(1-3):91-100. doi: 10.1016/j.regpep.2007.06.008. Epub 2007 Jul 6.
4
PET imaging of oncogene overexpression using 64Cu-vasoactive intestinal peptide (VIP) analog: comparison with 99mTc-VIP analog.使用64Cu-血管活性肠肽(VIP)类似物对癌基因过表达进行正电子发射断层显像(PET):与99mTc-VIP类似物的比较。
J Nucl Med. 2004 Aug;45(8):1381-9.
5
The functional investigation of a human adenocarcinoma cell line, stably transfected with the neuropeptide Y Y1 receptor.对稳定转染神经肽Y Y1受体的人腺癌细胞系进行功能研究。
Br J Pharmacol. 1996 Sep;119(2):321-9. doi: 10.1111/j.1476-5381.1996.tb15989.x.
6
Ropivacaine and lidocaine inhibit proliferation of non-transformed cultured adult human fibroblasts, endothelial cells and keratinocytes.罗哌卡因和利多卡因抑制未转化的培养成人人类成纤维细胞、内皮细胞和角质形成细胞的增殖。
Agents Actions. 1993 Sep;40(1-2):78-85. doi: 10.1007/BF01976755.
7
The vasoactive intestinal peptide receptor on intact human colonic adenocarcinoma cells (HT29-D4). Evidence for its glycoprotein nature.完整人结肠腺癌细胞(HT29-D4)上的血管活性肠肽受体。其糖蛋白性质的证据。
Biochem J. 1987 Feb 15;242(1):185-91. doi: 10.1042/bj2420185.
8
Molecular identification and structural requirement of vasoactive intestinal peptide (VIP) receptors in the human colon adenocarcinoma cell line, HT-29.人结肠腺癌细胞系HT-29中血管活性肠肽(VIP)受体的分子鉴定及结构要求
Biochem J. 1985 Oct 1;231(1):139-43. doi: 10.1042/bj2310139.
9
VIP receptors and control of short circuit current in the human intestinal clonal cell line Cl.19A.血管活性肠肽(VIP)受体与人类肠道克隆细胞系Cl.19A中短路电流的调控
Experientia. 1989 Dec 1;45(11-12):1102-5. doi: 10.1007/BF01950169.